> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Sterility Failures Flagged at Indian Injectable Drug Maker
- URL: https://www.fdaweb.com/sterility-failures-flagged-at-indian-injectable-drug-maker/
- Published: 2025-11-21T12:00:00.000Z
- Updated: 2026-09-14T15:27:30.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160264

FDA investigators have cited Immacule Lifesciences Private Limited, a sterile drug contract manufacturer in Himachal Pradesh, India, for extensive lapses in aseptic manufacturing, equipment design, environmental monitoring, and contamination prevention during a 10-day inspection in September. The findings are detailed in a just-posted lengthy [FDA Form 483](https://www.fda.gov/media/189747/download?ref=fdaweb.com).

Investigators documented repeated failures to follow basic procedures intended to prevent microbial contamination. During vial-filling operations, FDA says it observed that operators used sanitizing agents that caused blue marker ink from equipment labels to smear across laminar airflow (LAF) unit surfaces, then spread the ink—and potentially microbes—across cleanroom surfaces via contaminated wipes. FDA later confirmed the ink was easily removable by the same disinfectant routinely used in the filling suite, creating an ongoing contamination risk. Inspectors also found operators inadequately sanitizing LAF surfaces prior to environmental monitoring and failing to disinfect areas facing ISO 5 zones.

The agency also cited the vial filling line itself as poorly designed and overly reliant on operator interventions. During inspection of a line used for U.S.-market injectable products, FDA says it recorded frequent line stoppages and repeated operator reach-ins to clear fallen or un-stoppered vials—far exceeding the firm’s validated limits. FDA also observed cramped manufacturing spaces that required operators to push, pull, or maneuver large LAF units through narrow pathways, causing contact between equipment and surfaces from different cleanroom classifications. Scratches and dents on LAF units suggested repeated physical impacts.

Additionally, FDA says the firm lacked scientific justification for the placement of non-viable particle counters along critical portions of the filling line, including unmonitored segments where filled vials travel through high-risk areas. A 2022 “worst-case” company study failed to assess key sections of the line or account for operator interventions. Settle plates used for passive air monitoring were also positioned where they were fully blocked by sterile stopper bags during production, preventing any meaningful environmental sampling, the inspection form says.